has not yet been explored. We report here that pTregs are a key modifier of disease in the nonobesed diabetic (NOD) mouse model for T1D. We generated NOD mice deficient for the Foxp3 enhancer CNS1 involved in pTreg induction. We show that CNS1 knockout decreased the frequency of pTregs and increased the risk of diabetes. Our results show that pTregs fulfill an important non-redundant function in the prevention of beta cell autoimmunity that causes T1D.
Introduction
Type 1 diabetes (T1D) is an autoimmune disease in which autoreactive T cells destroy pancreatic beta cells, causing insulin deficiency. The T cells that drive pathogenesis can be held in check by
Foxp3
+ regulatory T cells (Tregs) [1] [2] [3] [4] . Several of the gene variants that increase the risk of T1D do so by diminishing the functionality of the Treg compartment. For example, gene variants in the IL-2 pathway that controls the frequency of circulating Tregs have been shown to associate with disease in mouse and human [5] [6] [7] . Therapeutic administration of low-dose IL-2 increases the frequency of Tregs and prevents autoimmune diabetes in mouse models [2, 4] . This approach is now in clinical trial for the prevention of T1D [8] . The success of low-dose IL-2 therapy in mice illustrates how manipulating the Treg compartment is a promising approach for the treatment of T1D. Yet, we do not fully understand the involvement of different Treg populations in the control of autoimmunity. The majority of Tregs emerge as a distinct population during thymic T cell maturation. Defects in thymic Treg development are a possible cause for the immune dysregulation that leads to autoimmune diabetes [9] [10] [11] . However, a proportion of mature Tregs forms not in the thymus but in the periphery [12, 13] . These Tregs, termed peripherally-induced or pTregs, derive from mature Foxp3 -CD4 + T cells following the encounter with tolerogenic stimuli, including TGF-β. The highest frequency of pTregs is found in the gut, likely owing to the capacity of gut microbes to promote pTreg induction [14] [15] [16] .
pTregs are also present in other organs, potentially contributing to systemic immune regulation, but to date, a role for pTregs has only been demonstrated in the gut [17] [18] [19] , in the lungs [17] and in fetal-maternal tolerance [20] . Whether pTregs participate in immune regulation in other organs is unclear. We set out to ask if pTregs have any role in pancreatic autoimmunity in the context of the nonobese diabetic (NOD) mouse model for T1D. Here, we report that the ability to ! 4 generate pTregs is a critical modifier of autoimmune diabetes.
Results

pTregs are present in the pancreas of NOD mice
Two cellular markers have been proposed to distinguish thymus-derived Foxp3 + CD4 + Tregs (tTregs) from pTregs. Helios and Neuropilin-1 (Nrp1) are both expressed at higher levels in tTregs than pTregs [22] [23] [24] . Preliminary measurements with Helios and Nrp1 suggested that the two markers were relatively well correlated, and we opted to focus on Helios because it has been suggested that pTregs may upregulate Nrp1 in inflamed tissues including the pancreas [13] . As reported previously, gut-associated lymphocytes harbored the highest frequency of pTregs. In the colonic lamina propria, 25-30% of all CD4 + T cells were Foxp3 + pTregs with low levels of Helios ( Fig. 1) . In contrast, pTregs were rare in the spleen. We detected a slightly higher frequency (~ 0.4% of CD4 + cells) in the mesenteric lymph node (mLN) closely associated with the gut. Interestingly, pTregs were also present at similar frequencies in both the pancreatic lymph node (pLN) and in the pancreas (Fig. 1B) . The pLN is a major site of activation for autoreactive T cells in autoimmune diabetes. The presence of pTregs in the pLN and in the pancreas suggests that pTregs could affect the autoimmune response that underlies T1D.
CNS1 deletion in NOD mice decreases the frequency of pTregs in the pancreas
The differentiation of pTregs involves tolerogenic stimuli that include TGFβ [25, 26] [21, 28] . CNS1 deletion was shown to decrease the frequency of pTregs [17, 27] . CNS1 knockout (KO) is the most specific perturbation available to modify the pTreg compartment without affecting tTregs. We generated CNS1 KO NOD mice using CRISPR-Cas9 genome editing ( Fig. 2A) . Briefly, we targeted the Cas9 endonuclease to sites immediately upstream and downstream of the CNS1 enhancer that is located at position +2079 relative to the Foxp3 promoter and spans some 630 nucleotides [21] . Two of the mice that developed from microinjected zygotes carried a mutated X-chromosome with the expected CNS1 deletion (Fig. 2B ). The CNS1 KO allele was inherited with Mendelian frequency and had no deleterious effects on development or fertility. We measured pTregs in the blood of founder CNS1 KO mice and their progeny, and confirmed that CNS1 deficiency decreased the frequency of pTregs ( Fig. 2C and 2D ). pTreg frequency was similarly reduced in the colon, spleen and lymph nodes of CNS1 KO NOD mice (Fig. 3B ), in accord with published data [27] . Importantly, CNS1 deletion also decreased Helios -Foxp3 + pTregs in the pLN and in the pancreas (Fig. 3B ).
Of note, CNS1 KO did not affect the frequency of tTregs or the frequency of total Foxp3 + Tregs , except in the colon (Fig. 3A) , presumably because the contribution of pTregs to the total Treg population is greatest in this organ. 
CNS1 deficiency increases the risk of autoimmune diabetes in NOD mice
We bred cohorts of CNS1 KO NOD mice using a breeding scheme that yielded WT and heterozygous (for females only, because Foxp3 is on the X-chromosome) control littermates for comparison. Mice were not separated by genotype at weaning and were co-housed throughout this study. CNS1 KO was reported to cause gastrointestinal pathology in the B6 mouse strain [17] , but not in a mixed 129/B6 background [27] . Unlike B6 mice, CNS1 KO NOD mice showed no signs of morbidity or weight loss up to 7 months of age, the period during which mice were monitored for diabetes. We found that CNS1 deficiency increased the frequency of diabetes in both male and female mice (Fig. 4A ). Insulitis was more severe in CNS1 KO mice compared with WT littermates (Fig. 4B ). We conclude that pTreg deficiency increases the risk of autoimmune diabetes.
Treg IL-10 production is decreased in the pancreas of CNS1 KO mice
To evaluate the extent of pTreg function in diabetes, we identified IL-10 producing (Fig. 4E ). Whether decreased IL-10 production itself is causal for increased diabetes frequency in CNS1 KO mice is uncertain, because IL-10 has been ascribed a positive [29] [30] [31] , negative [32] and neutral [33] role in pancreas autoimmunity by different studies.
Notwithstanding, the data show that pTregs impinge on the function of the pancreatic Treg compartment during autoimmune diabetes.
Discussion
The strongest genetic association with T1D is found in the HLA region [34] , implicating T cells as a major driver of autoimmune diabetes. Numerous additional disease-associated genomic regions relate to T cell function [34] [35] [36] . In particular, several of the gene variants thought to increase the risk of T1D pertain to the function and homeostasis of Tregs whose defect is thought to be a critical component of T1D pathogenesis [6] . Treg-based therapies are one of the most promising avenues for the treatment of autoimmunity. In this context, it is important that we better understand which Tregs could be leveraged to prevent or halt the autoimmune response that underlies T1D. pTregs may constitute a subset amenable to therapeutic manipulation, owing to the fact that these cells can be induced within the mature T cell population by various agents, including microbial metabolites [37] [38] [39] . While inducing pTregs appears feasible, the extent to which these cells contribute to the control of pancreatic autoimmunity had not yet been established. In this report, we showed that pTregs are present in the pancreas and that diminishing their frequency increases the risk of diabetes. Our findings support a role for pTregs in autoimmune diabetes. CNS1 KO was reported to have no effect in the experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis [17] . A role for pTregs in immune-mediated pathology may thus not be systemic, but has so far only been described in the gut [17] [18] [19] , the lungs [17] and in fetal-maternal tolerance [20] . The effect of pTregs on islet autoimmunity may relate to the proximity of the pancreas to the gut. The pLN is the primary site of activation for autoreactive T cells [40] in autoimmune diabetes. At the same time, the pLN is readily accessible to antigen and to cells from the gastrointestinal tract [41] , providing a direct route by which gut microbe-induced pTregs could impact autoimmunity in T1D. This speculative link would provide a plausible explanation for the effects of the gut microbiota on ! 8 autoimmune diabetes. It is now well established that diabetes in the NOD mouse model is very sensitive to changes in the microbiome [42] [43] [44] [45] . Similarly, prospective studies of human at-risk populations suggest that the gut microbiome modifies the risk of T1D [46, 47] . The effects of the microbiome on T1D may derive from the capacity of different microbial communities to promote the generation of pTregs relevant to pancreatic autoimmunity. In light of our finding that pTregs impact the risk of autoimmune diabetes, further exploring this putative mechanism is warranted. Additional research will be required to also determine when and where pTregs affect the autoimmune response that underlies T1D. A pTreg deficit in the gut could modify immune development locally or promote gut leakiness with systemic effects. Alternatively, loss of pTregs in the pLN and in the pancreas could have a direct effect on beta cell autoimmunity. It will also be important to determine at what stage pTregs exert their influence on disease. pTregs may be critical early during immune development when microbial effects on disease risk may be greatest [48] . Alternatively, pTregs may have the capacity to dampen autoimmunity throughout disease development. Notwithstanding the many facets of pTreg function that we do not yet understand, our study demonstrates that pTregs modify the risk of autoimmune diabetes, providing a strong incentive to further explore their role in T1D. 
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Materials and Methods
Mice
Lymphocyte Isolation
Single cell suspensions were prepared from spleen and lymph nodes by mechanical disruption of tissue followed by red blood cell lysis using ACK buffer. Colonic lamina propria cells were ! 10 isolated after removal of intraepithelial lymphocytes using EDTA followed by digestion with Collagenase Type VIII (Sigma Aldrich) and DNAse (Roche). Cells were collected using a Percoll (GE Healthcare) density gradient. Intra-pancreatic lymphocytes were harvested by digestion using Collagenase P (Roche) followed by a Histopaque-1077 (Sigma) density gradient.
Intracellular Cytokine Staining
Cells isolated from the pLN and pancreas were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) and 500 ng/ml ionomycine (Sigma-Aldrich) overnight at 37°C. Golgi-Stop (BD Biosciences) was added for the last 5 h of culture before staining and analysis by flow cytometry.
Flow Cytometry
Flow cytometry was performed using a LSRII instrument (BD Biosciences). Data were analyzed with the FlowJo software. Fluorescently conjugated CD4, CD8, IL-10, Helios and FoxP3 antibodies were purchased from Biolegend and eBioscience. Dead cells were excluded using the Zombie Aqua TM Fixable Viability Kit (Biolegend). Intracellular staining was performed with a FoxP3-labelling kit (eBioscience).
Diabetes Frequency Studies
Disease studies were performed with age-matched, contemporary cohorts of mice. Onset of diabetes was monitored by weekly measurements of glycosuria using Diastix (Bayer). Mice with two consecutive readings > 250 mg / dL were considered diabetic.
! 11
Insulitis and Immunohistochemistry
Pancreatic tissue was frozen in OCT (Fisher Scientific) prior to cryosectioning into 7 µm slices. 
Statistical Analyses
Data were analysed with the Prism software (Graphpad). Diabetes frequency comparisons were carried out using the Log-rank test. All other comparisons were performed using an unpaired ttest, with P < 0.05 considered significant. Sample sizes were approximated in initial experiments, and adjusted to increase power as needed in replicate experiments.
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Figure legends
